SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 5.50% Stake in Danimer Scientific
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a shared beneficial ownership of 5.50% of Danimer Scientific, Inc.'s Class A Common stock as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Danimer Scientific, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 171,761 shares of Danimer Scientific, Inc.'s Class A Common stock.
- This ownership represents 5.50% of the Class A Common stock outstanding.
- The percentage is calculated based on 3,125,187 shares outstanding as of November 12, 2024, as reported in Danimer Scientific's Form 10Q filed on November 19, 2024.
- Armistice Capital, LLC, acting as the investment manager for Armistice Capital Master Fund Ltd., exercises both voting and investment power over these securities.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
- The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain qualitative statements about the issuer's performance or outlook, thus maintaining a neutral sentiment.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor, providing transparency regarding significant stakes in publicly traded companies. It does not offer broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which may be viewed as a signal of institutional interest in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-11-12 | Date as of which 3,125,187 shares outstanding were reported in the Issuer's Form 10Q. |
| 2024-11-19 | Date the Issuer's Form 10Q was filed with the Securities and Exchange Commission. |
| 2024-12-31 | Date of event which requires filing of this statement (ownership snapshot date). |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Danimer Scientific, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, SEC Filing, Class A Common Stock, Investment Management, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.